Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies
{{output}}
Biogen Idec Inc, Genentech Inc, Roche Holding AG and Chugai Pharmaceutical Co Ltd are developing ocrelizumab, a humanized mAb against CD20, for the potential treatment of inflammatory disorders and B-cell malignancies. Ocrelizumab is undergoing phase III clini... ...
